AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines

Objective: Multiple myeloma (MM) is the clonal proliferation of neoplastic plasma cells in the bone marrow. Although bortezomib (BTZ) is a crucial drug for the treatment of MM, drug resistance is a major problem. OncomiR-19a plays an oncogenic role in many cancers, including MM; however, the functio...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Azam Kazemi, Saeid Abroun, Masoud Soleimani
Formato:	article
Lenguaje:	EN
Publicado:	Royan Institute (ACECR), Tehran 2021
Materias:	antagomir-19a bortezomib multiple myeloma socs3 Medicine R Science Q
Acceso en línea:	https://doaj.org/article/d0a174c47a674058bb15b47c9426b3fd
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d0a174c47a674058bb15b47c9426b3fd
record_format	dspace
spelling	oai:doaj.org-article:d0a174c47a674058bb15b47c9426b3fd2021-11-07T06:54:35ZAntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines10.22074/cellj.2021.73022228-58062228-5814https://doaj.org/article/d0a174c47a674058bb15b47c9426b3fd2021-10-01T00:00:00Zhttps://celljournal.org/journal/article/fulltext/induced-anti-mir-19a-overcomes-drug-resistance-in-myeloma-cell-lines.pdfhttps://doaj.org/toc/2228-5806https://doaj.org/toc/2228-5814Objective: Multiple myeloma (MM) is the clonal proliferation of neoplastic plasma cells in the bone marrow. Although bortezomib (BTZ) is a crucial drug for the treatment of MM, drug resistance is a major problem. OncomiR-19a plays an oncogenic role in many cancers, including MM; however, the function of miR-19a in the pathogenesis of MM and drug resistance has not been completely identified. The present research aims to investigate the inhibition of miR-19a by an antagomir to determine BTZ responsiveness, and determine if miR-19a can be a prognostic biomarker for MM. Materials and Methods: In this experimental study, viability and apoptosis of myeloma cells were analysed by the colorimetric 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT) and Annexin V/propidium iodide (PI) flow cytometry assays. Quantitative real-time polymerase chain reaction (qRT-PCR) was implemented to evaluate the expression levels of miR-19a, its targets SOCS3, STAT3, B-cell lymphoma 2 (BCL-2), PTEN and CDKN1A (antiapoptotic and cell cycle related genes) at the mRNA level. Results: miR-19a was downregulated and exacerbated in transfected cells treated with BTZ. The rate of apoptosis in the myeloma cells after BTZ treatment considerably increased, which indicated an increase in the mRNA of SOCS3, PTEN, BCL-2, and CDKN1. A decrease in STAT3 was also observed. Conclusion: OncomiR-19a, as a biomarker, may induce better responsiveness to BTZ in myeloma cell lines through its targets SOCS3, STAT3 and PTEN. In the future, this biomarker may provide new therapeutic targets for MM.Azam KazemiSaeid AbrounMasoud SoleimaniRoyan Institute (ACECR), Tehranarticleantagomir-19abortezomibmultiple myelomasocs3MedicineRScienceQENCell Journal, Vol 23, Iss 5, Pp 503-509 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	antagomir-19a bortezomib multiple myeloma socs3 Medicine R Science Q
spellingShingle	antagomir-19a bortezomib multiple myeloma socs3 Medicine R Science Q Azam Kazemi Saeid Abroun Masoud Soleimani AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines
description	Objective: Multiple myeloma (MM) is the clonal proliferation of neoplastic plasma cells in the bone marrow. Although bortezomib (BTZ) is a crucial drug for the treatment of MM, drug resistance is a major problem. OncomiR-19a plays an oncogenic role in many cancers, including MM; however, the function of miR-19a in the pathogenesis of MM and drug resistance has not been completely identified. The present research aims to investigate the inhibition of miR-19a by an antagomir to determine BTZ responsiveness, and determine if miR-19a can be a prognostic biomarker for MM. Materials and Methods: In this experimental study, viability and apoptosis of myeloma cells were analysed by the colorimetric 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide (MTT) and Annexin V/propidium iodide (PI) flow cytometry assays. Quantitative real-time polymerase chain reaction (qRT-PCR) was implemented to evaluate the expression levels of miR-19a, its targets SOCS3, STAT3, B-cell lymphoma 2 (BCL-2), PTEN and CDKN1A (antiapoptotic and cell cycle related genes) at the mRNA level. Results: miR-19a was downregulated and exacerbated in transfected cells treated with BTZ. The rate of apoptosis in the myeloma cells after BTZ treatment considerably increased, which indicated an increase in the mRNA of SOCS3, PTEN, BCL-2, and CDKN1. A decrease in STAT3 was also observed. Conclusion: OncomiR-19a, as a biomarker, may induce better responsiveness to BTZ in myeloma cell lines through its targets SOCS3, STAT3 and PTEN. In the future, this biomarker may provide new therapeutic targets for MM.
format	article
author	Azam Kazemi Saeid Abroun Masoud Soleimani
author_facet	Azam Kazemi Saeid Abroun Masoud Soleimani
author_sort	Azam Kazemi
title	AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines
title_short	AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines
title_full	AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines
title_fullStr	AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines
title_full_unstemmed	AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines
title_sort	antagomir-19a induced better responsiveness to bortezomib in myeloma cell lines
publisher	Royan Institute (ACECR), Tehran
publishDate	2021
url	https://doaj.org/article/d0a174c47a674058bb15b47c9426b3fd
work_keys_str_mv	AT azamkazemi antagomir19ainducedbetterresponsivenesstobortezomibinmyelomacelllines AT saeidabroun antagomir19ainducedbetterresponsivenesstobortezomibinmyelomacelllines AT masoudsoleimani antagomir19ainducedbetterresponsivenesstobortezomibinmyelomacelllines
_version_	1718443576969396224

AntagomiR-19a Induced Better Responsiveness to Bortezomib in Myeloma Cell Lines

Ejemplares similares